CT011 - A phase 1 multicenter study (TRAVERSE) evaluating the safety and efficacy of ALLO-316 following conditioning regimen in pts with advanced or metastatic clear cell renal cell carcinoma (ccRCC)

Researchers presented results of a single-arm phase 1 study of safety and preliminary efficacy of ALLO-316, a CAR T-cell therapy that targets the CD70 protein. CD70 is expressed in various solid tumors and highly expressed in metastatic clear cell renal carcinoma. Although it was a small study with just 17 patients with metastatic clear cell renal cell carcinoma, the objective response rate was 18%, and the disease control rate was 82%. When looking at the nine patients who had CD70-positive disease, these rates climbed to 33% and 100%, respectively.